PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC

被引：0
|
作者：
Liu, J. [1 ]
Zhou, H. [1 ]
Zhang, Y. [1 ]
Huang, Y. [1 ]
Yang, Y. [1 ]
Fang, W. [1 ]
Zhang, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
基金：
国家重点研发计划;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
320O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
    Zhou, Huaqiang
    Liu, Jiaqing
    Zhang, Yaxiong
    Huang, Yan
    Shen, Jiayi
    Yang, Yunpeng
    Fang, Wenfeng
    Zhang, Li
    NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [2] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
    Huaqiang Zhou
    Jiaqing Liu
    Yaxiong Zhang
    Yan Huang
    Jiayi Shen
    Yunpeng Yang
    Wenfeng Fang
    Li Zhang
    npj Precision Oncology, 4
  • [3] Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
    Braun, David A.
    Ishii, Yuko
    Walsh, Alice M.
    Van Allen, Eliezer M.
    Wu, Catherine J.
    Shukla, Sachet A.
    Choueiri, Toni K.
    JAMA ONCOLOGY, 2019, 5 (11) : 1631 - 1633
  • [4] The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).
    Hakimi, A. Ari
    Ged, Yasser
    Flynn, Jessica
    Hoen, Douglas R.
    Di Natale, Renzo G.
    Blum, Kyle A.
    Makarov, Vladimir
    Kuo, Fengshen
    Carlo, Maria Isabel
    Lee, Chung-Han
    Voss, Martin Henner
    Ostrovnaya, Irina
    Chan, Timothy An-thy
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Potential roles of PBRM1 on immune infiltration in cholangiocarcinoma
    Li, Ling
    Li, Yadan
    Guo, Yan
    Li, Jingyi
    Jin, Hongchuan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (10): : 2661 - 2676
  • [6] PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
    Dai, Jiali
    Cui, Yanan
    Liang, Xiao
    Xu, Jiali
    Li, Jun
    Chen, Yu
    Zhang, Erbao
    Guo, Renhua
    FRONTIERS IN GENETICS, 2023, 13
  • [7] PBRM1 loss promotes tumour response to immunotherapy
    Otto, Grant
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (03) : 134 - 135
  • [8] A germline mutation in PBRM1 predisposes to renal cell carcinoma
    Benusiglio, Patrick R.
    Couve, Sophie
    Gilbert-Dussardier, Brigitte
    Deveaux, Sophie
    Le Jeune, Helene
    Da Costa, Melanie
    Fromont, Gaelle
    Memeteau, Francoise
    Yacoub, Mokrane
    Coupier, Isabelle
    Leroux, Dominique
    Mejean, Arnaud
    Escudier, Bernard
    Giraud, Sophie
    Gimenez-Roqueplo, Anne-Paule
    Blondel, Christophe
    Frouin, Eric
    Teh, Bin T.
    Ferlicot, Sophie
    Bressac-de Paillerets, Brigitte
    Richard, Stephane
    Gad, Sophie
    JOURNAL OF MEDICAL GENETICS, 2015, 52 (06) : 426 - 430
  • [9] Impact of Chromatin Remodeling Genes Including SMARCA2 and PBRM1 on Neoantigen and Immune Landscape of NSCLC
    Park, L. C.
    Chang, S.
    Ko, T.
    Rhee, K.
    Anker, J.
    Bhave, M.
    Davis, A.
    Cruz, M.
    Iams, W.
    Zou, L.
    Wang, V.
    Chuang, J.
    Chae, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S525 - S525
  • [10] PBRM1 loss promotes tumour response to immunotherapy
    Grant Otto
    Nature Reviews Clinical Oncology, 2018, 15 : 134 - 135
12345